Jaber Emami-Baferani

List of Publications by Year
in descending order

40 papers	1,210 citations	279798 23 h-index	377865 34 g-index
40 all docs	40 docs citations	40 times ranked	1937 citing authors

#	Article	IF	Citations
1	Pulmonary Delivery of Docetaxel and Celecoxib by PLGA Porous Microparticles for Their Synergistic Effects Against Lung Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 951-967.	1.7	3
2	Pegylated multifunctional pH-responsive targeted polymeric micelles for ovarian cancer therapy: synthesis, characterization and pharmacokinetic study. International Journal of Polymeric Materials and Polymeric Biomaterials, 2021, 70, 1012-1026.	3.4	10
3	In Vitro and In Vivo Evaluation of Two Hydroxychloroquine Tablet Formulations: HPLC Assay Development. Journal of Chromatographic Science, 2021, 59, 71-78.	1.4	4
4	Novel pH-triggered biocompatible polymeric micelles based on heparinâ€“Î±-tocopherol conjugate for intracellular delivery of docetaxel in breast cancer. Pharmaceutical Development and Technology, 2020, 25, 492-509.	2.4	28
5	In Vitro and In Vivo Evaluation of Novel DTX-Loaded Multifunctional Heparin-Based Polymeric Micelles Targeting Folate Receptors and Endosomes. Recent Patents on Anti-Cancer Drug Discovery, 2020, 15, 341-359.	1.6	11
6	Development of a RP-HPLC method for analysis of docetaxel in tumor-bearing mice plasma and tissues following injection of docetaxel-loaded pH responsive targeting polymeric micelles. Research in Pharmaceutical Sciences, 2020, 15, 1.	1.8	6
7	Therapeutic drug monitoring of vancomycin by AUCÏ„-MIC ratio in patients with chronic kidney disease. Research in Pharmaceutical Sciences, 2019, 14, 84.	1.8	9
8	Receptor targeting drug delivery strategies and prospects in the treatment of rheumatoid arthritis. Research in Pharmaceutical Sciences, 2019, 14, 471.	1.8	11
9	PLGA-PEG-RA-based polymeric micelles for tumor targeted delivery of irinotecan. Pharmaceutical Development and Technology, 2018, 23, 41-54.	2.4	29
10	Targeted Nanostructured Lipid Carrier for Brain Delivery of Artemisinin: Design, Preparation, Characterization, Optimization and Cell Toxicity. Journal of Pharmacy and Pharmaceutical Sciences, 2018, 21, 225s-241s.	2.1	45
11	Preparation and characterization of an injectable thermosensitive hydrogel for simultaneous delivery of paclitaxel and doxorubicin. Research in Pharmaceutical Sciences, 2018, 13, 181.	1.8	29
12	Development and optimization of transferrin-conjugated nanostructured lipid carriers for brain delivery of paclitaxel using Boxâ€“Behnken design. Pharmaceutical Development and Technology, 2017, 22, 370-382.	2.4	45
13	Targeted Nanostructured Lipid Carriers for Delivery of Paclitaxel to Cancer Cells: Preparation, Characterization, and Cell Toxicity. Current Drug Delivery, 2017, 14, 1189-1200.	1.6	6
14	In vivopharmacokinetics, biodistribution and anti-tumor effect of paclitaxel-loaded targeted chitosan-based polymeric micelle. Drug Delivery, 2016, 23, 1-11.	5.7	35
15	Effects of probiotic drop containing Lactobacillus rhamnosus, Bifidobacterium infantis, and Lactobacillus reuteri on salivary Streptococcus mutans and Lactobacillus levels. Contemporary Clinical Dentistry, 2016, 7, 469.	0.7	10
16	A simple and sensitive high-performance liquid chromatography method for determination of ciprofloxacin in bioavailability studies of conventional and gastroretentive prolonged-release formulations. Advanced Biomedical Research, 2016, 5, 163.	0.5	5
17	Design and in vitro evaluation of a novel controlled onset extended-release delivery system of metoprolol tartrate. Research in Pharmaceutical Sciences, 2016, 11, 81-92.	1.8	7
18	A simple and sensitive HPLC method for analysis of imipramine in human plasma with UV detection and liquid-liquid extraction: Application in bioequivalence studies. Research in Pharmaceutical Sciences, 2016, 11, 168-76.	1.8	10

#	Article	IF	Citations
19	Development and in vitro/in vivo evaluation of a novel targeted polymeric micelle for delivery of paclitaxel. International Journal of Biological Macromolecules, 2015, 80, 29-40.	7.5	27
20	Co-delivery of paclitaxel andÎ±-tocopherol succinate by novel chitosan-based polymeric micelles for improving micellar stability and efficacious combination therapy. Drug Development and Industrial Pharmacy, 2015, 41, 1137-1147.	2.0	52
21	Formulation and optimization of celecoxib-loaded PLGA nanoparticles by the Taguchi design and theirin vitrocytotoxicity for lung cancer therapy. Pharmaceutical Development and Technology, 2015, 20, 791-800.	2.4	29
22	QUANTIFICATION OF PANTOPRAZOLE BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) METHOD: IN VITRO AND IN VIVO APPLICATIONS. Journal of Liquid Chromatography and Related Technologies, 2014, 37, 681-695.	1.0	7
23	Physicochemical, pharmaceutical and biological approaches toward designing optimized and efficient hydrophobically modified chitosan-based polymeric micelles as a nanocarrier system for targeted delivery of anticancer drugs. Journal of Drug Targeting, 2013, 21, 693-709.	4.4	35
24	Colon specific delivery of budesonide based on triple coated pellets: in vitro/in vivo evaluation. Acta Pharmaceutica, 2012, 62, 341-356.	2.0	7
25	Formulation of LDL Targeted Nanostructured Lipid Carriers Loaded with Paclitaxel: A Detailed Study of Preparation, Freeze Drying Condition, andIn VitroCytotoxicity. Journal of Nanomaterials, 2012, 2012, 1-10.	2.7	59
26	Preparation of budesonideâ€“dextran conjugates using glutarate spacer as a colon-targeted drug delivery system:in vitro/in vivoevaluation in induced ulcerative colitis. Journal of Drug Targeting, 2011, 19, 140-153.	4.4	32
27	Development of a prolonged-release gastroretentive tablet formulation of ciprofloxacin hydrochloride: Pharmacokinetic characterization in healthy human volunteers. International Journal of Pharmaceutics, 2011, 409, 128-136.	5.2	53
28	Microencapsulation of budesonide with dextran by spray drying technique for colon-targeted delivery: anin vitro/in vivoevaluation in induced colitis in rat. Journal of Microencapsulation, 2011, 28, 62-73.	2.8	24
29	Preparation and in vitro/in vivo evaluation of dextran matrix tablets of budesonide in experimental ulcerative colitis in rats. Drug Delivery, 2011, 18, 122-130.	5.7	12
30	The effect of process parameters on the size and morphology of poly(<scp>D,L</scp>â€lactideâ€coâ€glycolide) micro/nanoparticles prepared by an oil in oil emulsion/solvent evaporation technique. Journal of Applied Polymer Science, 2010, 116, 528-534.	2.6	6
31	Effectiveness of budesonide-succinate-dextran conjugate as a novel prodrug of budesonide against acetic acid-induced colitis in rats. International Journal of Colorectal Disease, 2010, 25, 1159-1165.	2.2	49
32	Pharmacokinetics and pharmacodynamics of controlled release insulin loaded PLGA microcapsules using dry powder inhaler in diabetic rats. Biopharmaceutics and Drug Disposition, 2010, 31, 189-201.	1.9	34
33	Influence of carrier particle size, carrier ratio and addition of fine ternary particles on the dry powder inhalation performance of insulin-loaded PLGA microcapsules. Powder Technology, 2010, 201, 289-295.	4.2	28
34	Effect of carrier morphology and surface characteristics on the development of respirable PLGA microcapsules for sustained-release pulmonary delivery of insulin. International Journal of Pharmaceutics, 2010, 389, 74-85.	5.2	46
35	Particle size design of PLGA microspheres for potential pulmonary drug delivery using response surface methodology. Journal of Microencapsulation, 2009, 26, 1-8.	2.8	45
36	A Novel Approach to Prepare Insulin-Loaded Poly (Lactic-Co-Glycolic Acid) Microcapsules and the Protein Stability Study. Journal of Pharmaceutical Sciences, 2009, 98, 1712-1731.	3.3	62

#	Article	IF	Citations
37	Synthesis and evaluation of dextranâ€“budesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis. International Journal of Pharmaceutics, 2009, 365, 69-76.	5.2	66
38	The effect of formulation variables on the characteristics of insulin-loaded poly(lactic-co-glycolic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7 Surfaces B: Biointerfaces, 2009, 74, 340-349.	5.0	60
39	In vitro - in vivo correlation: from theory to applications. Journal of Pharmacy and Pharmaceutical Sciences, 2006, 9, 169-89.	2.1	165
40	Formulation of sustained - release lithium carbonate matrix tablets: influence of hydrophilic materials on the release rate and in vitro-in vivo evaluation. Journal of Pharmacy and Pharmaceutical Sciences, 2004, 7, 338-44.	2.1	9